Search the Newsreel

Teva stock’s downward trend continues

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has experienced a continuous downward trend in its stock price, with falls on most trading days in July, causing its market cap to drop to $37.3 billion. Despite this, analyst Ori Hershkovitz maintains a "Buy" recommendation …

Roubaix Capital LLC Has $5.30 Million Holdings in Stevanato Group S.p.A. $STVN

Roubaix Capital LLC significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by 96.6% in the first quarter, now holding 385,316 shares valued at $5.3 million. Despite Stevanato Group missing Q1 EPS expectations, analysts maintain a constructive outlook, with recent upgrades and an outperform …

Allspring Global Investments Holdings LLC Sells 159,581 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Allspring Global Investments Holdings LLC reduced its stake in Teva Pharmaceutical Industries Ltd. by 8.7% in the first quarter, selling 159,581 shares and now owning 1,664,546 shares valued at approximately $50.4 million. This move comes as Teva insiders have also sold a significant number …

Bessemer Group Inc. Increases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Bessemer Group Inc. increased its stake in Teva Pharmaceutical Industries Ltd. by 1.6% in the first quarter, now owning 4.35 million shares valued at $131 million. Despite insider sales from executives like Mark Sabag and Christine Fox, analysts remain largely positive on Teva, holding …

Catalyst Capital Advisors LLC Acquires New Shares in Teva Pharmaceutical Industries Ltd. $TEVA

Catalyst Capital Advisors LLC significantly increased its stake in Teva Pharmaceutical Industries Ltd. by acquiring 40,900 shares valued at approximately $1.23 million in the first quarter. This move highlights ongoing institutional interest in Teva, with 54.05% of the stock now owned by institutional investors. …

Corteva, Inc. $CTVA Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp increased its stake in Corteva, Inc. (NYSE:CTVA) by 2.8% in the first quarter, now owning 0.70% of the company's stock valued at $394.93 million. Several other institutional investors also adjusted their positions in Corteva. The company has an …

Aware Super Pty Ltd as trustee of Aware Super Makes New Investment in Corteva, Inc. $CTVA

Aware Super Pty Ltd, as trustee of Aware Super, has initiated a new position in Corteva, Inc. (NYSE:CTVA) by acquiring 41,296 shares valued at approximately $3.46 million in the first quarter. Several other institutional investors also adjusted their holdings in Corteva during the same …

ETFs Investing in Corteva Inc Stocks

This article lists various ETFs that invest in Corteva Inc (1CTVA) stocks, providing financial details such as market value, weight, issuer, expense ratio, AUM, price change, relative volume, and 3-year NAV total return for each fund. The funds range from broad market ETFs to …

What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders

Teva Pharmaceutical Industries recently announced positive Phase 1b data for TEV-408 in vitiligo, showing improved repigmentation and safety, with plans for a Phase 2b trial backed by up to US$500 million in R&D funding. This development strengthens Teva's immunology pipeline and its strategic shift …

Responsive Playbooks and the CTVA Inflection

Corteva Inc. (NASDAQ: CTVA) is exhibiting neutral near-term sentiment but strong mid and long-term strength, characterized by a mid-channel oscillation pattern. The article identifies an exceptional 26.0:1 risk-reward short setup and outlines specific institutional trading strategies, including long, breakout, and risk-hedging plays, along with …

Corteva (NYSE:CTVA) Sets New 1-Year High - Time to Buy?

Corteva (NYSE:CTVA) recently reached a new 52-week high of $87.89, supported by positive analyst ratings and a consensus "Moderate Buy" rating with an average target of $88.95. The company also reported strong quarterly earnings, beating expectations with $1.50 EPS on $4.91 billion in revenue, …

Corteva stock hits all-time high at 87.75 USD

Corteva Inc. (CTVA) stock reached an all-time high of $87.75, with a strong year-to-date return of nearly 30% and a 1-year increase of 19.82%. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued. The agricultural giant is also preparing for a …

Corteva Highlights Transform Insecticide for Cotton Jassid Management

Corteva's Transform insecticide is being highlighted as an effective solution for managing cotton jassids, a new invasive pest in the southeastern U.S. University researchers and Corteva have collaborated on field trials, confirming Transform's efficacy against jassids, plant bugs, and aphids, while being less harmful …

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Rating of "Moderate Buy" by Brokerages

Teva Pharmaceutical Industries (NYSE: TEVA) has received a consensus "Moderate Buy" rating from brokerages, with nine out of ten analysts recommending the stock. The average 1-year price target is $41.78, and several firms recently raised their price targets on TEVA. Despite some insider selling, …

Corteva Inc. stock underperforms Thursday when compared to competitors despite daily gains

Corteva Inc. stock (CTVA) gained 2.61% on Thursday, reaching $86.65, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. However, the stock underperformed when compared to its unnamed competitors, even with its daily rise. This increase broke …

Corteva stands 2.3% from its high as Agricultural Inputs breadth sinks

The seed and crop-chemicals stock has separated from a weak Basic Materials cohort, but the latest week brought a pause, below-average volume and a still-negative activity-pressure read.

Kestra Advisory Services LLC Purchases 13,734 Shares of Corteva, Inc. $CTVA

Kestra Advisory Services LLC increased its stake in Corteva, Inc. by 19.8% in the first quarter, purchasing 13,734 shares to bring its total holdings to 83,060 shares valued at approximately $6.95 million. Corteva recently reported strong quarterly results, with earnings per share of $1.50 …

Diversify Wealth Management LLC Buys 54,488 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Diversify Wealth Management LLC significantly increased its stake in Teva Pharmaceutical Industries Ltd. by 734.3% in the first quarter, purchasing an additional 54,488 shares. This acquisition brings their total holdings to 61,908 shares, valued at approximately $1.87 million. While institutional ownership is high and …

Harel Insurance Investments & Financial Services Ltd. Increases Position in Teva Pharmaceutical Industries Ltd. $TEVA

Harel Insurance Investments & Financial Services Ltd. has increased its stake in Teva Pharmaceutical Industries Ltd. by 2.2% in the first quarter, making Teva its largest holding valued at approximately $1.38 billion. Teva reported a first-quarter EPS of $0.53 on revenue of $3.98 billion, …

Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap?

Teva Pharmaceutical Industries is gaining investor attention as its investigational anti-IL 15 antibody, TEV 408, advances to Phase 2b vitiligo trials and has FDA Fast Track status for celiac disease. Despite recent short-term share price dips, the company shows strong long-term returns, with its …

Teva’s 103.6% year leaves it near the high, but the latest lift came on 17.7M shares

The ADR remains in an active weekly Trend Signal and above its Trend Line, yet participation fell well below normal as the stock worked back toward the top of its 52-week range.

STVN Q1 2026 Earnings: EPS Beats Estimates, Stock Declines Amid Lack of Revenue Detail - Earnings Deceleration Risk

Stevanato Group (STVN) Earnings Date and Reports 2026

Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates

Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins

Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results